High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo.

Yuji Ikeda Sho Sato Akira Yabuno Daisuke Shintani Aiko Ogasawara Maiko Miwa Makda Getachew Zewde Takashi Miyamoto Keiichi Fujiwara Yusuke Nakamura Kosei Hasegawa

Published in: Journal of gynecologic oncology (2021)

We demonstrated MELK as both a prognostic marker and a therapeutic target for ovarian cancer using clinical ovarian cancer samples. MELK inhibition by OTS167 may be an effective approach to treat ovarian cancer patients.

Keyphrases

poor prognosis
signaling pathway
physical activity
birth weight
tyrosine kinase
pregnant women
pregnancy outcomes
protein kinase
long non coding rna
body mass index
gestational age